Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Photo: Getty Images

The embattled Canadian drug maker — which has been hit with stinging criticism from politicians for its big price hikes, and is subject to a related Congressional investigation — is now the target of a probe by the Securities Exchange Commission (SEC). 

Jack Craver


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.